The investigation by Levi & Korsinsky into Keros Therapeutics for potential securities fraud is significant as it follows the company's decision to halt parts of a clinical trial due to safety concerns. This could lead to legal and regulatory challenges, negatively impacting investor confidence and the stock price in the short term.